Vanguard Group
RXDX

Vanguard Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Vanguard Group’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,716,901
Closed -$292M – 4590
2023
Q1 		$292M Buy
2,716,901
+860,646
+46% +$99.1M 0.01% 1235
2022
Q4 		$204M Buy
1,856,255
+294,649
+19% +$19.1M 0.01% 1419
2022
Q3 		$92.2M Buy
1,561,606
+328,397
+27% +$15M ﹤0.01% 1837
2022
Q2 		$34.8M Buy
1,233,209
+31,667
+3% +$918K ﹤0.01% 2367
2022
Q1 		$45.4M Buy
1,201,542
+8,700
+0.7% +$344K ﹤0.01% 2352
2021
Q4 		$47.2M Buy
1,192,842
+649,933
+120% +$20.3M ﹤0.01% 2386
2021
Q3 		$12.9M Buy
542,909
+3,548
+0.7% +$83.7K ﹤0.01% 3098
2021
Q2 		$13.2M Buy
539,361
+419,361
+349% +$9.35M ﹤0.01% 3062
2021
Q1 		$2.19M Buy
+120,000
New +$2.48M ﹤0.01% 3840

Other funds holding RXDX

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
FCA
FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Vanguard Group's RXDX Position: Q2 2023 in Review

Vanguard Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,716,901 shares — an estimated $292M sold.

Vanguard Group first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $292M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

  • Vanguard Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Vanguard Group sold 2,716,901 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $292M.
  • Vanguard Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Vanguard Group's Prometheus Biosciences, Inc. Common Stock position peaked at $292M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.